CureVac (NASDAQ:CVAC) | Finanzwire

Basculer en Français

10497	Companies
221350	Keywords
150525	Articles
117045	Press releases

Home
Companies
CureVac

PRESS RELEASE

published on 11/04/2024 at 13:03, 1 year 6 months ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
CureVac appoints Axel Sven Malkomes as CFO, bringing 30 years of industry experience. His role will drive strategic initiatives, financial foundation, and shareholder value

Biopharmaceutical Company CFO MRNA Technology CureVac Axel Sven Malkomes
PRESS RELEASE

published on 11/04/2024 at 13:00, 1 year 6 months ago

CureVac to Present at the 12th International mRNA Health Conference
CureVac to present new data at the 12th International mRNA Health Conference, showcasing developments in mRNA cancer vaccine and lipid nanoparticle delivery technology

Innovation Biopharmaceutical CureVac MRNA Platform MRNA Health Conference
BRIEF

published on 10/28/2024 at 13:05, 1 year 7 months ago

CureVac to Present New Findings at SITC Annual Meeting

Clinical Trials MRNA Technology Cancer Vaccine CureVac SITC Meeting
PRESS RELEASE

published on 10/28/2024 at 13:00, 1 year 7 months ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided

CureVac MRNA Poster Presentation Immunogenicity Society For Immunotherapy Of Cancer
BRIEF

published on 09/13/2024 at 14:02, 1 year 8 months ago

CureVac's CVGBM Cancer Vaccine Shows Promising Results in Phase 1 Glioblastoma Study

CureVac Glioblastoma CVGBM Phase 1 Study T-cell Responses
PRESS RELEASE

published on 09/13/2024 at 13:57, 1 year 8 months ago

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose

Cancer Vaccine CureVac CVGBM Phase 1 Study Immune Responses
BRIEF

published on 09/12/2024 at 13:02, 1 year 8 months ago

CureVac and GSK Report Positive Phase 2 Data for Influenza mRNA Vaccine

MRNA Technology Influenza Vaccine Phase 2 Results GSK Partnership CureVac Milestone
PRESS RELEASE

published on 09/12/2024 at 12:57, 1 year 8 months ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac Partner GSK reports positive Phase 2 results for seasonal influenza mRNA vaccine program. Data show immune responses to A and B strains with acceptable safety profile

GSK CureVac Phase 2 MRNA Vaccine Seasonal Influenza
BRIEF

published on 09/09/2024 at 13:05, 1 year 8 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Clinical Data CureVac MRNA Vaccine Glioblastoma ESMO Congress
PRESS RELEASE

published on 09/09/2024 at 13:00, 1 year 8 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac to present first CVGBM Glioblastoma cancer vaccine clinical data at ESMO 2024 Congress. First-in-human study results to be shared, highlighting mRNA technology's potential for cancer vaccines

MRNA Technology CureVac Glioblastoma CVGBM ESMO 2024 Congress

Accesswire

Published on 06/03/2026 at 10:30, 1 hour 7 minutes ago

Silver Range Partner Excalibur Metals Intersects a Broad Precious Metals Zone, Open at Depth at the Bellehelen Property
Published on 06/03/2026 at 10:00, 1 hour 37 minutes ago

Eagle Plains and Xcite Define Prospective Geophysical Trends at Beaver River Uranium Project, SK
Published on 06/03/2026 at 09:05, 2 hours 32 minutes ago

2026 Letter to Nano One Stakeholders
Published on 06/03/2026 at 09:01, 2 hours 36 minutes ago

Apex Announces Drill Program Expansion and H2 Exploration Plans at the Rift Rare Earth Project
Published on 06/03/2026 at 04:58, 6 hours 39 minutes ago

Snipp Interactive Reports Q1 2026 Financial Results; Bookings Backlog Reaches Record $20.6 Million; Announces Conference Call on Wednesday, June 3, 2026

View all ACCESSWIRE

EQS Group

Published on 06/03/2026 at 11:14, 22 minutes ago

Notice of AGM
Published on 06/03/2026 at 11:00, 36 minutes ago

Notification of managers’ transactions
Published on 06/03/2026 at 10:20, 1 hour 16 minutes ago

WasabiCard, Payment Unicorn-in-the-making, Closes Pre-A, backed by Vernal Capital and Avenir Group, Vision Plus Capital, and 01VC
Published on 06/03/2026 at 10:15, 1 hour 21 minutes ago

Red Bull Basement Is Helping Founders Vibe Code Their Idea Into a Funded Startup Reality
Published on 06/03/2026 at 10:15, 1 hour 22 minutes ago

TenneT Germany receives MSCI ESG rating of AA

Les Echos

Published on 06/03/2026 at 11:29, 8 minutes ago

2026.06.03 Notice to holders of the Convertible Bond ISIN FR0013521085
Published on 06/03/2026 at 08:45, 2 hours 52 minutes ago

Air Liquide announces milestone investment in South Korea to support SK hynix’s advanced AI memory chip project
Published on 06/02/2026 at 18:03, 17 hours 33 minutes ago

Total number of voting rights and shares making up the share capital at May 31, 2026
Published on 06/02/2026 at 17:42, 17 hours 55 minutes ago

Aéroports de Paris SA - Shares and voting rights as of 31 May 2026
Published on 06/02/2026 at 17:40, 17 hours 57 minutes ago

Campus AI enters the implementation phase: Eiffage selected for deployment of shared infrastructure on the Fouju Campus in a deal worth over €120 million

View all LES ECHOS COMFI WIRE